These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7359537)

  • 41. Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7.
    Fragiadaki M; Magafa V; Borovicková L; Slaninová J; Cordopatis P
    Eur J Med Chem; 2007 Jun; 42(6):799-806. PubMed ID: 17316912
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synthesis of O-alkylated lysine-vasopressins, inhibitors of the antidiuretic response to lysine-vasopressin.
    Larsson LE; Lindeberg G; Melin P; Pliska V
    J Med Chem; 1978 Apr; 21(4):352-6. PubMed ID: 650663
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.
    Flouret G; Majewski T; Balaspiri L; Brieher W; Mahan K; Chaloin O; Wilson L; Slaninová J
    J Pept Sci; 2002 Jul; 8(7):314-26. PubMed ID: 12148781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Synthesis and some pharmacological properties of [1-(L-2-hydroxy-3-mercaptopropanoic acid), 4-threonine]oxytocin (hydroxy [4-thr]oxytocin), a peptide with strikingly high oxytocic potency and of [1-(L-2-hydroxy-3-mercaptopropanoic acid)]oxytocin (hydroxy-oxytocin).
    Manning M; Lowbridge J; Sawyer WH; Haldar J
    J Med Chem; 1976 Mar; 19(3):376-80. PubMed ID: 943546
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analogues of arginine vasopressin modified in the N-terminal part of the molecule with enantiomers of N-methylphenylalanine.
    Kowalczyk W; Derdowska I; Dawidowska O; Prahl A; Hartrodt B; Neubert K; Slaninová J; Lammek B
    J Pept Res; 2004 May; 63(5):420-5. PubMed ID: 15140159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [2-o-Iodotyrosine]-oxytocin and [2-o-methyltyrosine]-oxytocin: basic pharmacology and comments on their potential use in binding studies.
    Pliska V; Marbach P; Vasák J; Rudinger J
    Experientia; 1977 Mar; 33(3):367-9. PubMed ID: 558109
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist.
    Hauksson A; Akerlund M; Melin P
    Br J Obstet Gynaecol; 1988 Sep; 95(9):898-904. PubMed ID: 3191063
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Solid phase synthesis and some pharmacological properties of 8-D-homolysine-vasopressin and 1-deamino-8-D-homolysine-vasopressin.
    Gunnar E; Lindeberg G
    Int J Pept Protein Res; 1975; 7(5):395-401. PubMed ID: 1184288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. (1-Beta-mercaptopropionic acid, 2-(3,5-dibromo-L-tyrosine))oxytocin, a potent inhibitor of oxytocin.
    Lundell EO; Ferger MF
    J Med Chem; 1975 Oct; 18(10):1045-7. PubMed ID: 1159688
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides.
    Chen L; Zoulíková I; Slaninová J; Barany G
    J Med Chem; 1997 Mar; 40(6):864-76. PubMed ID: 9083475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Time-response patterns of isolated rat uterus to neurohypophyseal peptides.
    Wahrenburg M; Koida M; Walter R; Pliska V
    Experientia; 1975 Sep; 31(9):1062-4. PubMed ID: 1236807
    [No Abstract]   [Full Text] [Related]  

  • 52. Synthesis and some pharmacological properties of oxytocin and vasopressin analogues with sarcosine or N-methyl-L-alanine in position 7.
    Grzonka Z; Lammek B; Kasprzykowski F; Gazis D; Schwartz IL
    J Med Chem; 1983 Apr; 26(4):555-9. PubMed ID: 6187921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of potent antagonists of the vasopressor response to arginine-vasopressin.
    Bankowski K; Manning M; Haldar J; Sawyer WH
    J Med Chem; 1978 Sep; 21(9):850-3. PubMed ID: 722751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.
    Lowbridge J; Manning M; Seto J; Haldar J; Sawyer WH
    J Med Chem; 1979 May; 22(5):565-9. PubMed ID: 458806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin.
    Nestor JJ; Ferger MF; du Vigneaud V
    J Med Chem; 1975 Mar; 18(3):284-7. PubMed ID: 1133819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxytocin analogs with substitutions in postions 3 and 4.
    Roy J; Havran RT; Schwartz IL; Walter R
    Int J Pept Protein Res; 1975; 7(2):171-8. PubMed ID: 1140889
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of a uterine-type oxytocin receptor in the rat hippocampus.
    Mühlethaler M; Sawyer WH; Manning MM; Dreifuss JJ
    Proc Natl Acad Sci U S A; 1983 Nov; 80(21):6713-7. PubMed ID: 6314337
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Magnesium-neurohypophyseal hormone interactions in contraction of vascular smooth muscle.
    Altura BM
    Am J Physiol; 1975 May; 228(5):1615-20. PubMed ID: 1130565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conformationally biased analogs of oxytocin.
    Lebl M; Toth G; Slaninová J; Hruby VJ
    Int J Pept Protein Res; 1992 Aug; 40(2):148-51. PubMed ID: 1446971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Actions of vasopressin, oxytocin, and synthetic analogs on vascular smooth muscle.
    Altura BM; Altura BT
    Fed Proc; 1984 Jan; 43(1):80-6. PubMed ID: 6690341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.